Tris Pharma
Executivos
Veja o organograma con seus 16 executivos principais
Biografias mais buscadas da Tris Pharma
- Ketan Mehta, Chief Executive Officer and President
- Peter Ciano, Chief Financial Officer and Senior Vice President, Co...
- Cheryl Patnick, Senior Vice President, Human Resources and Adminis...
Recentes movimentos de executivos em Tris Pharma
- Michael Magee, ingressou na Companhia como Vice President, Quality and Compliance (Notícia publicada em 8 de fevereiro de 2024).
- Franchesca Fowler, ingressou na Companhia como Chief Compliance Officer, Vice President and General Counsel (Notícia publicada em 22 de janeiro de 2024).
Criar um alerta
para seguir os movimentos de executivos da Tris Pharma.
Farmacêutica
Tris Pharma possui 1.860 concorrentes concorrentes Pfizer (Estados Unidos), Sanofi (França) e Johnson & Johnson (Estados Unidos).
Popular M&A news in Farmacêutica
- MedMen has filed for bankruptcy protection (publicado em 28 de abril de 2024).
- AstraZeneca has announced the acquisition of Fusion Pharma (publicado em 23 de março de 2024).
- AstraZeneca has announced the acquisition of Amolyt Pharma (publicado em 19 de março de 2024).
Outros contatos sugeridos na indústria do Farmacêutica
Notícias
Últimos comunicados de imprensa de Tris Pharma
- Tris Pharma Launches Digital Health Business to Develop and Commercialize Digital Products for ADHD | Tris Pharma
- Tris Pharma Appoints Michael Magee as Vice President, Quality & Compliance | Tris Pharma
- Tris Pharma Appoints Franchesca Fowler to Chief Compliance Officer and Vice President, General Counsel | Tris Pharma
- Tris Pharma Partners with Perigon Pharmacy 360 to Enhance Access to DYANAVEL® XR Tablets for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Secures First ex-US Authorizations for Quillivant ER Oral Suspension and Quillivant ER Chewable Tablet for the Treatment of Attention Deficit Hyperactivity Disorder | Tris Pharma
- Tris Pharma Presents Data Reinforcing Limited Abuse Potential of Investigational Pain Therapy Cebranopadol at the 2023 PAINWeek Conference | Tris Pharma
- Tris Pharma Awarded Five-Year Grant of Up to $16.6M From the NIH's National Institute on Drug Abuse to Advance Cebranopadol for the Treatment of Opioid Use Disorder | Tris Pharma
- Tris Pharma Expands Leadership Team as Company Broadens Commercial Portfolio and Progresses Clinical Pipeline | Tris Pharma
- Tris Pharma Announces FDA Approval of DYANAVEL® XR (amphetamine) Once-Daily Extended-Release Oral Tablets, CII, for ADHD | Tris Pharma
- Tris Pharma® Hires Seasoned Business Development Executive Anthony Amato joins as Executive Vice President Business Development – Generics Division | Tris Pharma
- View more press releases Close
Redes sociais sobre Tris Pharma
- Tris Pharma na Wikipedia, Google News e Yahoo Finance
- Tris Pharma na LinkedIn, Twitter e YouTube
Entrar em contato
Contate seus executivos por e-mail agora, incluindo Ketan Mehta 
Ligue para a Tris Pharma em +1 732...
